Development of AD-Like Pathology in Skeletal Muscle.
Development of AD-Like Pathology in Skeletal Muscle.
复制标题
DOI：
10.13188/2376-922x.1000028
复制
发表时间：
2019-01-01
期刊：
影响因子：
--
通讯作者：
Geiger, J D
中科院分区：
文献类型：
--
作者：
Chen, X;Miller, N M;Geiger, J D
针对阿尔茨海默病（AD）的有效治疗策略需要早期检测AD;然而，阿尔茨海默病（AD）的临床诊断并不精确，并且AD的明确诊断仅可能通过对AD病理学标志（包括由Abeta组成的老年斑和由磷酸化tau组成的神经元缠结）的尸检来进行。虽然已经开发了多种生物标志物并用于临床环境，但它们中没有一种能够有力地预测AD的后续临床病程。因此，有必要确定新的生物标志物，可能有助于诊断早期阶段的AD，预测随后的临床过程，并开发新的治疗策略。考虑到AD的病理学标志，包括A β积聚和磷酸化tau的存在，也在外周组织中检测到，AD被认为是一种全身性疾病。由于缺乏血脑屏障的保护，全身性因素对周围组织的影响要比脑内神经元的影响早得多。在这里，我们将讨论AD样病理在骨骼肌中的发展和骨骼肌活检（检查A β积聚和磷酸化tau蛋白）作为AD生物标志物的潜在用途。
Effective therapeutic strategy against Alzheimer's disease (AD) requires early detection of AD; however, clinical diagnosis of Alzheimer's disease (AD) is not precise and a definitive diagnosis of AD is only possible via postmortem examination for AD pathological hallmarks including senile plaques composed of Abeta and neuro fibrillary tangles composed of phosphorylated tau. Although a variety of biomarker has been developed and used in clinical setting, none of them robustly predicts subsequent clinical course of AD. Thus, it is essential to identify new biomarkers that may facilitate the diagnosis of early stages of AD, prediction of subsequent clinical course, and development of new therapeutic strategies. Given that pathological hallmarks of AD including Abetaaccumulation and the presence of phosphorylated tau are also detected in peripheral tissues, AD is considered a systemic disease. Without the protection of blood-brain barrier, systemic factors can affect peripheral tissues much earlier than neurons in brain. Here, we will discuss the development of AD-like pathology in skeletal muscle and the potential use of skeletal muscle biopsy (examination for Abetaaccumulation and phosphorylated tau) as a biomarker for AD.